Venus Concept Inc (VERO)

Venus Concept's stock experienced a surge in January 2026 due to Madryn Asset Management increasing its ownership stake, but later reversed some gains. The company announced its intention to voluntarily delist from the Nasdaq in January 2026 to reduce costs and focus on operational execution. The stock price has generally been falling, with a 70.810% decline over the past year. A debt-to-equity exchange transaction was announced on October 2, 2025. The company's revenue decreased by 15.09% in 2024, and losses increased by 26.2%. Management has cited ongoing challenges such as customer financing pressures, economic uncertainty, high interest rates, and tighter credit markets.

Specific information regarding the demand seasonality for Venus Concept's products and services is not explicitly detailed. Historically, Venus Concept's stock has "tanked over 4% on average in February," indicating a historical pattern in stock price movement. The company has also cited general macroeconomic headwinds as ongoing challenges impacting its business.

Venus Concept, Inc. is a global medical technology company focused on minimally invasive and non-invasive medical aesthetic and hair restoration technologies. The company operates in the Healthcare sector, specifically in the Surgical Appliance and Supplies Manufacturing industry and Medical Specialties. Venus Concept offers a range of aesthetic device platforms for body, face, and skin treatments, and previously offered NeoGraft and ARTAS iX for hair restoration, but entered an agreement to sell its Venus Hair business in June 2025.

Venus Concept has a global presence, with its technologies available in over 60 countries and operating in 9 direct markets. The majority of its revenue is generated from the United States, and its operations are segmented into United States and International geographical segments.

Information directly detailing Venus Concept's brand reputation or specific events affecting it in the past year is limited. The company's financial performance, characterized by declining revenues, high operating losses, and significant debt burdens, could indirectly impact its reputation among investors and in the market. Historically, in 2018, the FDA expressed concerns regarding the marketing of Venus Fiore for vaginal rejuvenation procedures, leading to investigations into potential lawsuits.

Venus Concept has a concentrated ownership structure, with Madryn Asset Management holding a significant stake of 91%. Major institutional owners and shareholders include Essex Woodlands Management, Inc., DRW Securities, LLC, UBS Group AG, Vanguard Extended Market Index Fund Investor Shares (VEXMX), Tower Research Capital LLC (TRC), Citigroup Inc, SBI Securities Co., Ltd., Morgan Stanley, BlackRock, Inc., and Bank Of America Corp /de/. Individual investors, particularly Michael Willingham Masters, own the most shares. Approximately 92.31% of Venus Concept (VERO) stock is held by retail investors, while institutional investors hold about 7.03% and insiders hold 0.66%.